Considering the findings in the pre-clinical models consistently showing exacerbation of underlying cardiovascular pathologies with CGRP inhibition it is important to address whether CGRP blockade may exacerbate current cardiovascular disease or increase the severity of cardiovascular events that happen and also whether there is a difference between monoclonal antibodies targeted toward the CGRP receptor or peptide (MaassenVanDenBrink et al., 2016). The gene discussed is CALCA; the disease is cardiovascular disorder.